Drugs / Cromolyn
last change Aug 2026 re-read 2 minutes ago

Cromolyn

Small molecule

Developed for
triple-negative breast carcinoma · Alzheimer disease · amyotrophic lateral sclerosis · chronic prostatitis · COVID-19 · cutaneous mastocytosis · eosinophilic esophagitis · exercise-induced bronchoconstriction
+11 more · lung adenocarcinoma · mastocytosis · psoriasis · rosacea · tick-borne infectious disease · upper respiratory tract disorder · viral pneumonia · cognitive disorder · schizoaffective disorder · schizophrenia · stroke disorder
Investigated by
Fudan University · LEO Pharma · AZTherapies, Inc. · Algemeen Ziekenhuis Maria Middelares · Aradign Corportation · Carcinex Inc
+20 more · Columbia University · Jessa Hospital · Joseph Butterfield · National Heart, Lung, and Blood Institute (NHLBI) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Northwestern University · Patara Pharma · PhenoNet, Inc. · Pulmotect, Inc. · Respivant Sciences GmbH · Shiraz University of Medical Sciences · Texas Tech University Health Sciences Center, El Paso · The University of Texas Medical Branch, Galveston · Universitaire Ziekenhuizen KU Leuven · University of California, San Diego · University of California, San Francisco · University of North Carolina, Chapel Hill · University of Tennessee · University of Texas · WCCT Global

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) NASALCROM 2001-03-27 fda.gov
Label expansion US (FDA) OPTICROM 1993-06-11 fda.gov
Approved US (FDA) INTAL 1982-05-28 fda.gov

Trials 20 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT03167216 Aug 2017 → Apr 2022 chronic prostatitis Northwestern University Completed No outcome recorded
Phase 15 trials
Phase 1 NCT07675876 Aug 2026 → Jun 2027 expected lung adenocarcinoma Carcinex Inc Not yet recruiting No outcome recorded
Phase 1 NCT04570644 Aug 2020 → Jan 2021 Alzheimer disease AZTherapies, Inc. Completed No outcome recorded
Phase 1 NCT04007120 Oct 2019 → May 2020 lung disorder Respivant Sciences GmbH Completed No outcome recorded
Phase 1 NCT01841307 Jul 2015 → Mar 2017 gastroesophageal reflux disease, idiopathic pulmonary fibrosis University of California, San Francisco Terminated No outcome recorded
Phase 1 NCT02566252 Jul 2015 → Jan 2016 Pulmotect, Inc. Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT01933464 Aug 2013 → Feb 2014 rosacea University of California, San Diego Completed No outcome recorded
Phase 29 trials
Phase 2 NCT07526558 Apr 2026 → Jan 2027 expected tick-borne infectious disease University of North Carolina, Chapel Hill Not yet recruiting No outcome recorded
Phase 2 NCT07419880 Jan 2026 → Jan 2027 expected triple-negative breast carcinoma Fudan University Not yet recruiting No outcome recorded
Phase 2 NCT07142291 Nov 2025 → Mar 2027 expected amyotrophic lateral sclerosis PhenoNet, Inc. Recruiting No outcome recorded
Phase 2 NCT05076682 Jun 2022 → Dec 2026 expected triple-negative breast carcinoma Fudan University Recruiting No outcome recorded
Phase 2 NCT04846348 Jul → Sep 2021 cutaneous mastocytosis Joseph Butterfield Terminated No outcome recorded
Phase 2 NCT02412020 Feb 2015 → Jan 2016 upper respiratory tract disorder Patara Pharma Completed No outcome recorded
Phase 2 NCT01722812 Nov 2012 → Apr 2013 psoriasis LEO Pharma Completed No outcome recorded
Phase 2 NCT01701843 Oct 2012 → Feb 2013 mastocytosis LEO Pharma Terminated No outcome recorded
Phase 2 NCT00745199 May → Nov 2008 end stage renal failure Shiraz University of Medical Sciences Completed No outcome recorded
Phase 33 trials
Phase 3 NCT06801626 Mar 2025 → Dec 2026 expected The University of Texas Medical Branch, Galveston Recruiting No outcome recorded
Phase 3 NCT05077917 Nov 2021 → May 2024 COVID-19, viral pneumonia Texas Tech University Health Sciences Center, El Paso Terminated No outcome recorded
Phase 3 NCT04408664 Apr 2021 → Jun 2023 exercise-induced bronchoconstriction Universitaire Ziekenhuizen KU Leuven Terminated No outcome recorded
Phase 41 trial
Phase 4 NCT02371941 Dec 2014 → Jul 2017 eosinophilic esophagitis University of Tennessee Completed No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT03794076 Comparator Apr 2019 → Jan 2028 expected schizoaffective disorder, schizophrenia Vishwajit Nimgaonkar, MD PhD Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT03202147 Comparator Dec 2023 → Dec 2024 cognitive disorder, ischemic stroke AZTherapies, Inc. Withdrawn No outcome recorded
Phase 31 trial
Phase 3 NCT01175525 Comparator stroke disorder Wolfson Medical Center Unknown No outcome recorded

Evidence & citations 65 cited values

Every value below carries the sentence it was read from. 24 sources stand behind the page.

FieldValueCited text
Known as Cromolyn ClinicalTrials.gov intervention name — accepted as the source's own label NCT07142291
5

NCT07419880

NCT01841307

NCT03202147

NCT04570644

NCT01175525

Known as Acide cromoglicique ChEMBL registry synonym — accepted as the source's own label CHEMBL428880
Known as Acido cromoglicico ChEMBL registry synonym — accepted as the source's own label CHEMBL428880
Known as Aerocrom ChEMBL registry synonym — accepted as the source's own label CHEMBL428880
Known as Allercrom ChEMBL registry synonym — accepted as the source's own label CHEMBL428880
Known as ALZT-OP1a ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)” NCT04570644
Known as Aspire ChEMBL registry synonym — accepted as the source's own label CHEMBL428880
Known as Astilyn ChEMBL registry synonym — accepted as the source's own label CHEMBL428880
Known as Brol-eze ChEMBL registry synonym — accepted as the source's own label CHEMBL428880
Known as Catacrom ChEMBL registry synonym — accepted as the source's own label CHEMBL428880
Known as Clariteyes ChEMBL registry synonym — accepted as the source's own label CHEMBL428880
Known as Crolom ChEMBL registry synonym — accepted as the source's own label CHEMBL428880
Known as Cromo-comod ChEMBL registry synonym — accepted as the source's own label CHEMBL428880
Known as Cromogen ChEMBL registry synonym — accepted as the source's own label CHEMBL428880
Known as Cromogen e-breathe ChEMBL registry synonym — accepted as the source's own label CHEMBL428880
Known as Cromoglicate ClinicalTrials.gov intervention name — accepted as the source's own label NCT01701843
1

NCT01722812

Known as Cromoglicate sodium ChEMBL registry synonym — accepted as the source's own label CHEMBL428880
Known as Cromoglicic acid ChEMBL registry synonym — accepted as the source's own label CHEMBL428880
Known as Cromoglycate ClinicalTrials.gov intervention name — accepted as the source's own label NCT03794076
Known as Cromoglycic acid ChEMBL registry synonym — accepted as the source's own label CHEMBL428880
Known as Cromolux ChEMBL registry synonym — accepted as the source's own label CHEMBL428880
Known as Cromolyn disodium salt ChEMBL registry synonym — accepted as the source's own label CHEMBL428880
Known as Cromolyn Sodium “RVT-1601, a new inhalation formulation of cromolyn sodium delivered via the eFlow® Closed System (CS) nebulizer/face mask.” NCT04007120
10

“Drug: Cromolyn SodiumNCT01841307

NCT05077917

NCT02371941

NCT06801626

NCT01933464

NCT02566252

NCT07526558

NCT07675876

NCT00745199

NCT03167216

Known as Cromolyn, Intal, Cromolyn Sodium, Sodium cromoglycate Cromolyn, Intal, Cromolyn Sodium, Sodium cromoglycateNCT04570644
Known as Cromoptic ChEMBL registry synonym — accepted as the source's own label CHEMBL428880